A strategy to improve the cardiovascular risk factor profile in renal transplant patients;Uma estratégia para redução de risco cardiovascular em pacientes transplantados renais

Arquivos Brasileiros de Cardiologia

Volumn 94, Issue 6, 2010, Pages 738-746

  Leite, Denise ^a   Campos, Alexandre Holthausen ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiovascular diseases prevention and control; Kidney transplantation; Patients; Risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BRAZIL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HEALTH STATUS; HUMANS; HYPERTENSION; KIDNEY TRANSPLANTATION; LIFE STYLE; LIPIDS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RISK ASSESSMENT; RISK FACTORS; SMOKING; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955595032     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2010005000055     Document Type: Article

References (30)

1. Rigatto C. Clinical epidemiology of cardiac disease in renal transplant recipients. Semin Dial. 2003; 16 (2): 106-10.
2. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000; 356 (9224): 147-52.
3. McLean DR, Jardine AG. A simulation model to investigate the impact of cardiovascular risk in renal transplantation. Transp Proc. 2005; 37 (5): 2135-43.
4. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000; 11 (9): 1735-43.
5. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 1995; 60 (5): 451-7.
6. Mozzafarian D, Kamineni A, Prineas RJ, Siscovick DS. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med. 2008; 168 (9): 969-78.
7. Rigatto C. Management of cardiovascular disease in the renal transplant recipient. Cardiol Clin. 2005; 23 (3): 331-42.
8. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361 (9374): 2024-31.
9. Jardine AG, Fellstrom B, Logan JO, Cole E, Nyberg G, Grönhagen-Riska C, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005; 46 (3): 529-36.
10. Holdaas H. Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy? Am J Cardiovasc Drugs. 2005; 5 (4): 255-69.
11. Holdaas H, Fellstrom B, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant. 2005; 20 (5): 974-80.
12. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005; 45 (3): 473-84.
13. Eagle KA, Gallogly M, Mehta RH, Baker PL, Blount A, Freundl M, et al. Taking the national guideline for care of acute myocardial infarction to the bedside: developing the guideline applied in practice (GAP) initiative in Southeast Michigan. Jt Comm J Qual Improv. 2002; 28 (1): 5-19.
14. Medina-Pestana JO. Organization of a high-volume kidney transplant program- the "assembly line" approach. Transplantation. 2006; 81(11): 1510-20.
15. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341 (23): 1725-30.
16. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis. 1998; 32 (5 Suppl 3): S5-S13.
17. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004; 4 (Suppl 7): 13-53.
18. Kasiske BL. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients. Am J Transplant. 2005; Jun;5(6):1576.
19. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int. 2004; 66 (1): 441-7. (Pubitemid 38870123)
20. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97 (18): 1837-47. (Pubitemid 28213628)
21. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988; 84 (6): 985-92.
22. Massy ZA, Mamzer-Bruneel MF, Chevalier A, Millet P, Helenon O, Chadefaux- Vekemans B, et al. Carotid atherosclerosis in renal transplant recipients. Nephrol Dial Transplant. 1998; 13 (7): 1792-8.
23. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32 (5 Suppl 3): S112-9.
24. Lauer MS. Clinical practice: aspirin for primary prevention of coronary events. N Engl J Med. 2002; 346 (19): 1468-74.
25. Mollmann H, Elsasser A, Hamm CW. Oral antithrombotic therapy in primary and secondary prevention. Herz. 2005; 30 (3): 181-8.
26. Tendera M, Wojakowski W. Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb Res. 2003; 110 (5-6): 355-9. (Pubitemid 37329839)
27. Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant. 2005; 5 (11): 2710-8.
28. Cofan F, Vela E, Cleries M. Obesity in renal transplantation: analysis of 2691 patients. Transplant Proc. 2005; 37 (9): 3695-7.
29. Ehlers SL, Rodrigue JR, Patton PR, Lloyd-Turner J, Kaplan B, Howard RJ. Treating tobacco use and dependence in kidney transplant recipients: development and implementation of a program. Prog Transplant. 2006; 16 (1): 33-7.
30. Ho PM, Peterson PN, Masoudi FA. Evaluating the evidence: Is there a rigid hierarchy? Circulation. 2008; 118 (16):1675-84.